Boehringer puts a tar­get on Hu­mi­ra, says push­ing it off for­mu­la­ries is nec­es­sary

For biosim­i­lars to win, Ab­b­Vie has to lose, ac­cord­ing to Boehringer In­gel­heim.

The Ger­man drug­mak­er on Wednes­day said that its goal of get­ting more up­take …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.